

---

**21 October 2022**

**ASX:GLH**

**Global Health Ltd September 2022**

**Quarterly Business Activity Report & Appendix 4C**

Melbourne, Australia – Healthcare software provider **Global Health Ltd (ASX: GLH)** (“Global Health”) is pleased to release its **Appendix 4C Cash Flow Report** for the quarter ended 30 September 2022, along with a **Quarterly Business Activity Report**.

**Financial Highlights**

- Net operating cashflow deficit for the quarter of \$1.71m
- The balance sheet remains strong, underpinned by a cash balance of \$4.22m

Further P&L Highlights:

- Growth in recurring revenues to \$1.38m in Q1 FY2023, representing an 18% increase from \$1.17m for the corresponding period in FY2022
- Total customer revenue increase of 11% to \$1.61m in Q1FY2023 compared to \$1.45m for the corresponding period in FY2022 due to revenue from new contract wins
- Australian operating costs increased by 17% to \$1.1m for the quarter compared to \$0.95m for the corresponding period in FY2022. This was as a result of planned recruitment and sales focus in line with our growth strategy
- Global Health's Singapore subsidiary incurred operating costs of \$0.25m in Q1 FY2023 representing the initial investment to establish our presence in the wider ASEAN market

The above financial results are reflective of our continued and planned investment in key personnel, a high focus on sales initiatives, Research and Development and emerging ASEAN expansion.

The Company's sales pipeline and near-term prospects remain strong, with more detail provided in our Business Activity and Forward Outlook sections below.

---

In accordance with Listing Rule 4.7C.1, the expenditures of Global Health for the quarter ended 30 September 2022 are set out in the table below:

Expense Category	Amount (\$A'000)
Product manufacturing and operating costs	854
Advertising and marketing	63
Leased Assets	46
Staff costs	1,606
Administration and corporate costs	315
Interest and other costs of finance paid	3
Property, plant and equipment	4
Research and product development	412
Loans to other entities	11
Repayment of borrowings (HP Finance)	35

In accordance with Listing Rule 4.7C.3, payments to related parties and their associates during the quarter totalled \$116K. This related to directors' remuneration (\$105K) and a loan to an associate company (\$11K).

---

## Business Activity & New Contracts

During the first quarter of FY23 we have secured some significant new business wins:

- Yarram District Health Services
- Homeless Health Care
- Arcadia Health Care
- La Trobe Community Health

The contracted sales from Q1 2023 represent a greater contracted revenue volume than was secured in the entire FY22 financial year.

## Forward Outlook & Growth Strategy

We see opportunity in delivering solutions for private hospitals managing large backlogs of operations/surgeries where digitisation can bring efficiencies alongside using our vast mental health expertise gained over more than 10 years to support in the delivery of mental and community health services as government investment comes online.

In addition to the new contracts announced above, Global Health has a high level of confidence in the near-term of signing additional contracts that will have a material impact on FY2023 revenue. We look forward to announcing all new contracts as they are signed. Global Health is pleased with its recent wins and current prospect pipeline and feels it is well positioned for further growth in FY2023.

We see opportunity in ASEAN markets of Vietnam, Malaysia, Thailand and Philippines where low rates of medical practitioners drive demand for digital solutions and corporate accounts where solutions can help manage healthcare costs and encourage preventative care.

Initial investments and activity in the ASEAN market are tracking to plan and the development of an initial pipeline is progressing well.

We also continue to explore M&A opportunities with synergistic organisations.

**This announcement was approved for lodgement by the Board.**

– ENDS

---

---

For further information please contact:

**Michael Davies**

**Chief Executive Officer, Global Health Limited**

**M:** 0429 306 650

**E:** [Michael.davies@global-health.com](mailto:Michael.davies@global-health.com)

**Rod North - Investor Relations, Media & PR**

**Managing Director, Bourse Communications**

**M:** 0408 670 706

**E:** [rod@boursecommunications.com.au](mailto:rod@boursecommunications.com.au)

**About Global Health Limited**

**Global Health (ASX: GLH)** is a leading provider of Digital Health solutions to the Australian Healthcare Industry. Innovation, consumer-centricity and connectivity are the foundations of the Company's vision of 'Connecting Clinicians and Consumers.'

Global Health helps streamline the delivery of healthcare services and provide better health outcomes across various health sectors, including acute and community settings.

Global Health offers a range of tailored software and SaaS solutions helping health businesses to be more efficient and deliver excellent patient care. These include electronic medical records for health delivery organisations, client management systems for community health, patient administration systems for hospitals, practice management systems, secure messaging for connected care, patient engagement platforms and consumer health records.

Located in Melbourne, Victoria the company is ISO27001 compliant.

Find out more about Global Health Solution's at [www.global-health.com](http://www.global-health.com)

---

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

**Name of entity**

Global Health Limited

**ABN**

75 091 377 892

**Quarter ended ("current quarter")**

30 September 2022

<b>Consolidated statement of cash flows</b>	<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
<b>1. Cash flows from operating activities</b>		
1.1 Receipts from customers	1,181	1,181
1.2 Payments for		
(a) research and development	-	-
(b) product manufacturing and operating costs	(854)	(854)
(c) advertising and marketing	(63)	(63)
(d) leased assets	(46)	(46)
(e) staff costs	(1,606)	(1,606)
(f) administration and corporate costs	(315)	(315)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	-	-
1.5 Interest and other costs of finance paid	(3)	(3)
1.6 Income taxes paid	-	-
1.7 Government grants and tax incentives	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (3 months) \$A'000</b>
1.8	Other (provide details if material)	-	-
<b>1.9</b>	<b>Net cash from / (used in) operating activities</b>	<b>(1,706)</b>	<b>(1,706)</b>

<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(4)	(4)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	(412)	(412)
2.2	Proceeds from disposal of:		
	(g) entities	-	-
	(h) businesses	-	-
	(i) property, plant and equipment	-	-
	(j) investments	-	-
	(k) intellectual property	-	-
	(l) other non-current assets	-	-
2.3	Cash flows from loans to other entities	(11)	(11)
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(427)</b>	<b>(427)</b>

<b>3.</b>	<b>Cash flows from financing activities</b>	-	-
-----------	---	---	---

3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	(35)	(35)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>(35)</b>	<b>(35)</b>

<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	6,376	6,376
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(1,706)	(1,706)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(427)	(427)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(35)	(35)
4.5	Effect of movement in exchange rates on cash held	13	13
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>4,221</b>	<b>4,221</b>

<b>5. Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1 Bank balances	4,221	6,376
5.2 Call deposits	-	-
5.3 Bank overdrafts	-	-
5.4 Other (provide details)	-	-
<b>5.5 Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>4,221</b>	<b>6,376</b>

<b>6. Payments to related parties of the entity and their associates</b>	<b>Current quarter \$A'000</b>
6.1 Aggregate amount of payments to related parties and their associates included in item 1 *	105
6.2 Aggregate amount of payments to related parties and their associates included in item 2 **	11

*Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.*

*\* Payments associated with item 6.1 relate to directors' fees/directors' remuneration.*

*\*\*Payments associated with item 6.2 relate to a loan to an associate company.*

<b>7. Financing facilities</b>  <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i>  <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	25	15
7.3 Other (please specify)	107	107
<b>7.4 Total financing facilities</b>	<b>132</b>	<b>122</b>
<b>7.5 Unused financing facilities available at quarter end</b>	<b>10</b>	
<b>7.6</b> Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
<p><b>7.2</b> Lender: Australia and New Zealand Banking Group Limited (ANZ) Company Credit Card Facility Interest rate: Up to 8-week Interest free period. Otherwise, 17.74% per annum on purchases if unpaid by the due date. 19.24% per annum on cash advances. Secured/unsecured: Unsecured</p> <p><b>7.3</b> Lender: HP Financial Services (Australia) Pty Ltd Interest rate: 8.5% per annum Maturity date: June 2023 Secured/unsecured: Unsecured</p>		

<b>8.</b>	<b>Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1	Net cash from / (used in) operating activities (item 1.9)	(1,706)
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,221
8.3	Unused finance facilities available at quarter end (item 7.5)	10
8.4	Total available funding (item 8.2 + item 8.3)	4,231
8.5	<b>Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	<b>2.48</b>
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
	Answer: N/A	
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
	Answer: N/A	
	8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
	Answer: N/A	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

---

## Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 21 October 2022

Authorised by: Board of Directors

## Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
  2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
  3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
  4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – e.g. Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
  5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.
-